The interaction between PF4 and the antibody can initiate platelet actication, hence increasing the risk of thrombosis.[9] Therefore, specific antibodies in COVID-19, especially anti-PF4 might affect platelet activation and resultant thrombosis.[7,8]. The gene discussed is PF4; the disease is deep vein thrombosis.